Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF)

Assessment of the safety and tolerability of PLN-74809 following daily administration for up to 28 days in patients with idiopathic pulmonary fibrosis
Donna Griffiths at dgriffiths@pennstatehealth.psu.edu or 717-531-5519
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT04396756
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged 50 years or older
Idiopathic Pulmonary Fibrosis (IPF) diagnosis
Exclusion Criteria:
Receiving non-approved agents to treat IPF
Need for continuous oxygen supplementation >15 hours/day
Active lung or sinus infection
Active smoker
Hepatic impairment or end-stage liver disease
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA